Latest Regulatory News

Ainsworth Game Technology reported a 10% revenue increase to AUD 290.8 million for 2025 but posted a net loss of AUD 19.2 million, driven by a significant goodwill impairment and foreign currency headwinds. The company’s strategic investments and market challenges set the stage for a pivotal year ahead.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Metro Mining has delivered a remarkable turnaround in 2025, posting record shipments and profits, while announcing a strategic share buy-back and debt extension to underpin future growth.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.

Kina Securities Limited reported a 20% increase in statutory net profit after tax to PGK 120.7 million for 2025, driven by strong revenue growth and loan book expansion. The bank declared a higher final dividend and anticipates continued earnings growth in 2026 amid favourable economic conditions and tax cuts.

Bass Oil reported steady January production with a notable regulatory green light for its Vanessa gas field acquisition and a $3.5 million grant to accelerate the Kiwi gas field development.

Raiz Invest Limited reported a robust half-year performance for the period ending 31 December 2025, with revenue climbing 23.9% and a return to profitability driven by increased customer engagement and funds under management.

Structural Monitoring Systems PLC reported a 31% revenue increase to AUD 16.5 million for H1 2025, driven by strong avionics growth and improved profitability despite ongoing litigation and leadership changes.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

FIN Resources has completed the acquisition of the Cabin Lake Gold Project in Canada’s Northwest Territories, securing key permits and preparing for a fully funded drilling campaign starting in March 2026.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.